Italy Meningococcal Vaccines Market Size & Outlook
Italy meningococcal vaccines market, 2018-2030 (US$M)
Related Markets
Italy meningococcal vaccines market highlights
- The Italy meningococcal vaccines market generated a revenue of USD 67.2 million in 2021 and is expected to reach USD 126.6 million by 2030.
- The Italy market is expected to grow at a CAGR of 7.3% from 2022 to 2030.
- In terms of segment, bivalent was the largest revenue generating type in 2021.
- Quadrivalent is the most lucrative type segment registering the fastest growth during the forecast period.
Meningococcal vaccines market data book summary
| Market revenue in 2021 | USD 67.2 million |
| Market revenue in 2030 | USD 126.6 million |
| Growth rate | 7.3% (CAGR from 2021 to 2030) |
| Largest segment | Bivalent |
| Fastest growing segment | Quadrivalent |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Bivalent, Quadrivalent |
| Key market players worldwide | Pfizer Inc, Sanofi SA, GSK PLC, Merck & Co Inc, Serum Institute of India Pvt. Ltd., Walvax Biotechnology |
Other key industry trends
- In terms of revenue, Italy accounted for 2.3% of the global meningococcal vaccines market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK meningococcal vaccines market is projected to lead the regional market in terms of revenue in 2030.
- Russia is the fastest growing regional market in Europe and is projected to reach USD 27.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Meningococcal Vaccines Market Scope
Meningococcal Vaccines Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Italy meningococcal vaccines market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to meningococcal vaccines market will help companies and investors design strategic landscapes.
Bivalent was the largest segment with a revenue share of 60.42% in 2021. Horizon Databook has segmented the Italy meningococcal vaccines market based on bivalent, quadrivalent covering the revenue growth of each sub-segment from 2018 to 2030.
The meningococcal vaccines market in Italy is expected to grow at a lucrative rate owing to increasing vaccine uptake, rising recommendations, and growing disease burden in the country. In 2018, the incidence of IMD was 0.9 per 100,000 population in the country. Moreover, MCV4 is recommended to people aged 18 & below.
Government initiatives to increase meningitis vaccination to combat the growing number of cases are anticipated to accelerate market growth. For instance, according to report published by Nature, vaccination coverage in Italy has increased due to the expansion of mandatory vaccination laws in 2017.
It was observed that the number of infants vaccinated were 36% in 2017, which increased to 75% in 2018. In 2017, Italy implemented the meningococcal B vaccine in its National Immunization Program. The vaccine is recommended for all infants aged 2 months to 2 years in 3 + 1 vaccination schedule.
Reasons to subscribe to Italy meningococcal vaccines market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Italy meningococcal vaccines market databook
-
Our clientele includes a mix of meningococcal vaccines market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy meningococcal vaccines market , including forecasts for subscribers. This country databook contains high-level insights into Italy meningococcal vaccines market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Italy meningococcal vaccines market size, by type, 2018-2030 (US$M)
Italy Meningococcal Vaccines Market Outlook Share, 2021 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
